 |
This article needs additional citations for verification. Please help improve this articlebyadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Iovance Biotherapeutics" – news · newspapers · books · scholar · JSTOR (November 2019) (Learn how and when to remove this message) |
 | |
| Formerly | Lion Biotechnologies, Inc. |
|---|---|
| Company type | Public |
|
| |
| Industry |
|
| Founded | 2007; 17 years ago (2007) |
| Headquarters | San Carlos, California, U.S. |
Key people | Steven Rosenberg |
Number of employees | 319 (December 31, 2021) |
| Website | iovance |
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.[3]
In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[4]
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceuticalorbiotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
